Calypso taps Vertatschitsch as CEO

Clint vanSonnenberg | | Health Imaging | Artificial Intelligence
Calypso Medical Technologies has named Edward Vertatschitsch, PhD, as the company's president and CEO.

Vertatschitsch, who has served as executive vice president of operations as well as research and development, and is currently interim CEO, has worked with Calypso for seven years. Previously, Vertatschitsch managed hardware development at Palm, where he managed the development of the PDA, after serving as chief scientist at Boeing.

Vertatschitsch earned his PhD in electrical engineering from McMaster University in Ontario. Calypso develops real-time localization technology for tumor-tracking and is headquartered in Seattle.

Clint vanSonnenberg

Related Content

AI reduces CT lung cancer screening workload by nearly 80%
How AI and CCTA help heart teams plan ahead before PCI
5 steps for evaluating radiology AI applications
Adaptable AI system detects subtle changes in imaging, has potential across multiple clinical settings
New algorithm models radiologists' eye movements to interpret chest X-rays
Embracing the future: James Min left academia to push for a paradigm shift in preventive cardiology

Around the web

Radiology Business
Shift toward imaging outside the hospital could save billions

Harvard’s David A. Rosman, MD, MBA, explains how moving imaging outside of hospitals could save billions of dollars for U.S. healthcare.

Cardiovascular Business
‘A significant milestone’: First US patients receive doses of new PET radiotracer for CAD

Back in September, the FDA approved GE HealthCare’s new PET radiotracer, flurpiridaz F-18, for patients with known or suspected CAD. It is seen by many in the industry as a major step forward in patient care. 

Cardiovascular Business
Continuation of 99mTc-PYP shortage prompts need for alternative cardiac amyloidosis imaging

After three years of intermittent shortages of nuclear imaging tracer technetium-99m pyrophosphate, there are no signs of the shortage abating.